Literature DB >> 18326352

Tb drug resistance: is it really a threat to Africa?

Paul Nunn1, Matteo Zignol, Ernesto Jaramillo, Abigail Wright, Haileyesus Getahun.   

Abstract

In most of the world and particularly in Eastern Europe, China and India, drug resistance is increasingly seen as a major threat to tuberculosis (TB) control and even to public health and health security. What about in Africa? The conditions for creation of drug resistance exist in most, if not all, African countries, as a result of underinvestment in basic TB control, poor management of anti-TB drugs and virtual absence of infection control measures. The severity of drug resistance is increasing--following outbreaks all over the world of multi-drug resistant TB (MDR) in the 1990's, extensive drug resistant (XDR) TB has now been found in 37 countries, including South Africa. (MDR is, in essence, resistance to the most powerful first-line drugs, and XDR-TB is TB resistant to the most powerful second-line drugs as well.) Worse still, the impact of XDR-TB is magnified among those with HIV infection, giving rise to a remarkably high mortality, and exposing significant weaknesses in both HIV and TB control. In particular, the lack of laboratories capable of carrying out culture and drug susceptibility testing severely limits the capacity of countries even to detect the problem in Africa. This paper analyses the threat of TB drug resistance to health and to TB control in Africa, and puts forward measures to diminish this threat.

Entities:  

Mesh:

Year:  2007        PMID: 18326352

Source DB:  PubMed          Journal:  Ethiop Med J        ISSN: 0014-1755


  2 in total

Review 1.  Managing tuberculosis and HIV in sub-Sahara Africa.

Authors:  Umesh G Lalloo; Sandy Pillay
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

2.  Risk factors for multidrug-resistant tuberculosis among tuberculosis patients: a case-control study.

Authors:  Abdulhalik Workicho; Wondwosen Kassahun; Fessahaye Alemseged
Journal:  Infect Drug Resist       Date:  2017-03-13       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.